bluebird bio, Inc. Equity-NMS: BLUE

Healthcare

Biotechnology

Buy/Sell an entire stock
or a fraction.

Vested

Already an existing customer?

New User?

Open Your Free Demat Account And Start Trading Seamlessly

Loading, Please wait...

Error in Fetching Data, Please retry later.

No data available.

Previous close :

$4.97

1Y :

23.28%

5Y :

-98.79%

What is the share price of bluebird bio, Inc. today?

bluebird bio, Inc. (BLUE) share price as of February 28, 2026, is $4.97. If you are investing from India, you can always check the valuation in the INR before investing.

Can Indian Investors purchase shares of bluebird bio, Inc.?

Yes, Indian Investors can invest in the bluebird bio, Inc. (BLUE) Share by opening an international trading account with Angel One.

How can I purchase bluebird bio, Inc. shares in India?

Purchasing bluebird bio, Inc. (BLUE) share from India can be done by:

Directly: By opening an international trading account with Angel One. The process would include KYC verification.
The account activation takes a few minutes to a few hours, after which you can start buying bluebird bio, Inc. (BLUE) by making deposits in US dollars.
Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.

Can I buy Fractional shares of bluebird bio, Inc.?

Yes, you can purchase fractional shares of bluebird bio, Inc. (BLUE) or any other US company shares in Angel One for any dollar amount.

What is the market capitalization value of bluebird bio, Inc.?

The market capitalization of bluebird bio, Inc. on February 28, 2026, is $0.

In which sector bluebird bio, Inc. belongs?

bluebird bio, Inc. operates in the Healthcare sector, specifically in the Biotechnology industry.

What documents are required to invest in bluebird bio, Inc. stocks?

In order to invest in bluebird bio, Inc. (BLUE) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.)

From start to end, the process is digital and can be seamless.

bluebird bio, Inc. is a biotechnology company. The Company is focused on researching, developing and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. It markets three gene therapies: ZYNTEGLO (betibeglogene autotemcel, also known as beti-cel), SKYSONA (elivaldogene autotemcel, also known as eli-cel), and LYFGENIA (lovotibeglogene autotemcel, also known as lovo-cel). ZYNTEGLO is the first gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions. SKYSONA is used to slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). LYFGENIA is used for the treatment of sickle cell disease in patients ages 12 and older who have a history of vaso-occlusive events (VOEs).